Nathanael L. Dirks, Ph.D.
Affiliations: | 2010 | Pharmaceutical Sciences | University of Tennessee Health Science Center, Memphis, TN, United States |
Area:
PharmacyGoogle:
"Nathanael Dirks"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Bernd Meibohm | grad student | 2010 | UTHSC | |
| (Population pharmacokinetics of therapeutic monoclonal antibodies: Examples and estimation method performance differences.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Okamoto H, Dirks NL, Rosario M, et al. (2020) Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intestinal Research |
| Chen C, Rosario M, Polhamus D, et al. (2020) Sa1868 AN EVALUATION OF THE EXPOSURE-EFFICACY RELATIONSHIP FOR SUBCUTANEOUS VEDOLIZUMAB MAINTENANCE TREATMENT OF CROHN'S DISEASE: PHARMACOKINETIC FINDINGS FROM VISIBLE 2 Gastroenterology. 158: S-458 |
| Osterman MT, Rosario M, Lasch K, et al. (2019) Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Alimentary Pharmacology & Therapeutics |
| Zhu R, Zheng Y, Dirks NL, et al. (2017) Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. Pulmonary Pharmacology & Therapeutics |
| Rosario M, Dirks NL, Milch C, et al. (2017) A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clinical Pharmacokinetics |
| Rosario M, Dirks NL, Gastonguay MR, et al. (2016) Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease Alimentary Pharmacology and Therapeutics. 42: 188-202 |
| Osterman M, Gastonguay MR, Lasch K, et al. (2016) Vedolizumab Efficacy Exposure-Response Relationship for Ulcerative Colitis Patients (GEMINI I) Based on Causal Inference Analysis American Journal of Gastroenterology. 111: S294 |
| Rosario M, French J, Dirks N, et al. (2014) P489 Exposure-response relationship during vedolizumab induction therapy in adults with ulcerative colitis Journal of Crohn's and Colitis. 8: S270-S271 |
| Rosario M, French J, Dirks N, et al. (2014) P488 Exposure-response relationship of vedolizumab after 6 weeks of treatment in adults with Crohn's disease Journal of Crohn's and Colitis. 8: S270 |
| Rosario M, Dirks N, Gastonguay M, et al. (2014) P385 Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease Journal of Crohn's and Colitis. 8: S225-S226 |